Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA3 | P07451 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725811 | 0.91 | MAPT (0.32) | MAPTHPGDCYP3A4BLMPMP22 | |
| SCHEMBL3615251 | 0.82 | ALDH1A1 (0.41) | LMNAMAPTPKMCA3CA14 | |
| SCHEMBL3566684 | 0.80 | ALOX5 (0.44) | LMNAALDH1A1RAB9A | |
| SCHEMBL449124 | 0.80 | — | — | |
| SCHEMBL4920991 | 0.80 | ALOX5 (0.43) | CA2LMNAHPGDCA1ALDH1A1 | |
| SCHEMBL320721 | 0.80 | KCNN4 (0.42) | CA2CA1ALDH1A1 | |
| SCHEMBL526060 | 0.80 | NPC1 (0.42) | CA2LMNAMAPTCA1CYP3A4 | |
| SCHEMBL1681249 | 0.79 | NPSR1 (0.46) | CA2LMNAMAPTHTTCA1 | |
| SCHEMBL6897141 | 0.78 | TSHR (0.50) | CA2CA1CA12CA9CA3 | |
| SCHEMBL14674701 | 0.77 | CYP2A6 (0.47) | MAPTHPGDTYRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| EP-0397511-B1 | Novel cephalosporin compounds and processes for preparation thereof | LUCKY LTD (KR) | 1996-09-04 | — | — | EP | disclosed |
| US-5202315-A | Antiboiotic | LUCKY, LTD. (KR) | 1993-04-13 | — | — | US | disclosed |
| WO-1992008721-A1 | NOVEL CEPHALOSPORIN COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | LUCKY, LTD. (KR) | 1992-05-29 | — | — | WO | disclosed |
| EP-0397511-A2 | Novel cephalosporin compounds and processes for preparation thereof | LUCKY, LTD. (KR) | 1990-11-14 | — | — | EP | disclosed |
| US-4816235-A | Silver and manganese recovery using acidified thiourea | PESIC BATRIC (US) | 1989-03-28 | — | — | US | disclosed |
| US-4778519-A | Recovery of precious metals from a thiourea leach | PESIC BATRIC (US) | 1988-10-18 | — | — | US | disclosed |
| US-3994719-A | Resins for separating heavy metals consisting of thiourea-group-containing macroporous vinyl aromatic crosslinked matrixes | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | CA2 3419/4885PEPD 2057/4885ESR1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.